Colin Zhang
Impact in
-
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
-
- Cell Adhesion Molecules Research
Papers in
-
- Monoclonal and Polyclonal Antibodies Research 3
- Oncology 4
- Peptidase Inhibition and Analysis 4
- HER2/EGFR in Cancer Research 3
- Co-authors
- Shinji Sakai (4 shared papers)Yasunori Okano (2 shared papers)David Burns (2 shared papers)Qiyan Lin (1 shared paper)Yunlong Li (1 shared paper)Jin‐Cong Zhuo (2 shared papers)Meizhong Xu (2 shared papers)Chunhong He (2 shared papers)
- Journals
- Bioorganic & Medicinal Chemistry Letters (3 papers)Journal of Medicinal Chemistry (2 papers)International Journal of Bioprinting (1 paper)Synlett (1 paper)Cancer Research (1 paper)
- Partner nations
- United StatesJapanChina
In The Last Decade
Colin Zhang
12 papers receiving 306 citations
Peers
Comparison fields: 5 of 57
- Oncology 140
- Immunology and Allergy 31
- Cancer Research 41
- Radiology, Nuclear Medicine and Imaging 59
- Molecular Biology 143
Countries citing papers authored by Colin Zhang
This map shows the geographic impact of Colin Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colin Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colin Zhang more than expected).
Fields of papers citing papers by Colin Zhang
This network shows the impact of papers produced by Colin Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colin Zhang. The network helps show where Colin Zhang may publish in the future.
Co-authors
The 25 scholars most cited alongside Colin Zhang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2006 | 152 | |
| 2 | 2021 | 58 | |
| 3 | 2007 | 28 | |
| 4 | 2024 | 25 | |
| 5 | 2007 | 12 | |
| 6 | 2022 | 8 | |
| 7 | 2022 | 8 | |
| 8 | 2007 | 7 | |
| 9 | 2024 | 6 | |
| 10 | Discovery and characterization of INCB028060, a novel, potent and selective Met RTK inhibitor for cancer treatment | 2008 | 4 |
| 11 | 2009 | 4 | |
| 12 | 2020 | 2 | |
| 13 | 2024 | 0 | |
| 14 | 2025 | 0 | |
| 15 | 2025 | 0 | |
| 16 | 2025 | 0 |
About Colin Zhang
Colin Zhang is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Automotive Engineering, Biomedical Engineering and Nephrology, having authored 16 papers that have together received 314 indexed citations. Recurring topics across this work include 3D Printing in Biomedical Research (4 papers), Peptidase Inhibition and Analysis (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), HER2/EGFR in Cancer Research (3 papers), Additive Manufacturing and 3D Printing Technologies (2 papers), Innovative Microfluidic and Catalytic Techniques Innovation (2 papers), Synthetic Organic Chemistry Methods (1 paper) and Parathyroid Disorders and Treatments (1 paper). The work is most often cited by research in Oncology (140 citations), Immunology and Allergy (31 citations), Cancer Research (41 citations), Radiology, Nuclear Medicine and Imaging (59 citations) and Molecular Biology (143 citations). Colin Zhang has collaborated with scholars based in United States, Japan and China. Frequent co-authors include Shinji Sakai, Yasunori Okano, David Burns, Qiyan Lin, Yunlong Li, Jin‐Cong Zhuo, Meizhong Xu, Chunhong He, Eric Shi and Ding‐Quan Qian. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry, International Journal of Bioprinting, Synlett and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.